Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer

The immune checkpoint inhibitor atezolizumab is approved for PD-L1-positive triple-negative breast cancer (TNBC). However, no activity of atezolizumab in PD-L1-negative TNBC has been reported to date. Here, we present the case study of a woman with TNBC with low tumor infiltrating lymphocytes and PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Brasó-Maristany, Fara, Sansó, Miriam, Chic, Nuria, Martínez, Débora, González-Farré, Blanca, Sanfeliu, Esther, Ghiglione, Lucio, Carcelero, Esther, Garcia-Corbacho, Javier, Sánchez, Marcelo, Soy, Dolors, Jares, Pedro, Peg, Vicente, Saura, Cristina, Muñoz, Montserrat, Prat, Aleix, Vivancos, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489403/
https://www.ncbi.nlm.nih.gov/pubmed/34616675
http://dx.doi.org/10.3389/fonc.2021.710596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489403/
https://www.ncbi.nlm.nih.gov/pubmed/34616675
http://dx.doi.org/10.3389/fonc.2021.710596

Ejemplares similares